VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy 2022 | Novel allo-CART therapies and their role in the treatment of hematological malignancies

Roman Galetto, PhD, Cellectis, Paris, France, briefly discusses some novel allogeneic chimeric antigen receptor T-cell (CAR-T) therapies being developed for the treatment of various hematological indications, including B-cell acute lymphoblastic leukemia (B-ALL), acute myeloid leukemia (AML), multiple myeloma, and other B-cell malignancies. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Disclosures

Cellectis employee

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter